InvestSMART

Burgundy Diamond Mines Limited (ASX: BDM) - Announcements

- Current share price for BDM : $0.017

ASX company news and announcements for Burgundy Diamond Mines Limited (BDM) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Burgundy Diamond Mines Limited (BDM) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Burgundy Diamond Mines Limited (BDM), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Burgundy Diamond Mines Limited (BDM)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$24 Appendix 4C - quarterly 30 Jan 2009 10:43AM n/a $0.017 n/a
$24 Phase II data of H5 vaccine confirms safety, immunogenicity 5 Dec 2008 9:49AM n/a $0.017 n/a
$24 BioDiem receives 6th milestone of US$1m for flu vaccine 28 Nov 2008 1:28PM $0.080 $0.017 fallen by 78.75%
$24 Appendix 4C - quarterly 31 Oct 2008 1:09PM $0.075 $0.017 fallen by 77.33%
$24 Extension of Co-operative Research and Development Agreement 20 Oct 2008 9:20AM $0.075 $0.017 fallen by 77.33%
$24 Preliminary Final Report 29 Aug 2008 3:29PM $0.110 $0.017 fallen by 84.55%
$24 Appendix 4C - quarterly 24 Jul 2008 9:48AM $0.115 $0.017 fallen by 85.22%
$24 Appendix 4C - quarterly 30 Apr 2008 2:43PM $0.240 $0.017 fallen by 92.92%
$24 Target market expands for BioDiem`s Flu vaccine 29 Feb 2008 9:14AM $0.185 $0.017 fallen by 90.81%
$24 Half Year Accounts 26 Feb 2008 4:10PM $0.140 $0.017 fallen by 87.86%
$24 Appendix 4C - quarterly 24 Jan 2008 3:01PM $0.160 $0.017 fallen by 89.38%
$24 BioDiem receives 5th milestone of US$1m for flu vaccine 26 Nov 2007 9:45AM $0.210 $0.017 fallen by 91.90%
$24 Appendix 4C - quarterly 16 Oct 2007 11:55AM $0.265 $0.017 fallen by 93.58%
$24 Open Briefing 11 Oct 2007 9:31AM $0.290 $0.017 fallen by 94.14%
$24 BDM-E Phase I/II trial results 9 Oct 2007 9:54AM $0.290 $0.017 fallen by 94.14%
$24 BioDiem raises $7m in placement 9 Oct 2007 9:44AM $0.290 $0.017 fallen by 94.14%
$24 Preliminary Final Report 30 Aug 2007 9:41AM $0.200 $0.017 fallen by 91.50%
$24 BioDiem completes treatment in phase I/II study of eye drug 13 Aug 2007 10:17AM $0.240 $0.017 fallen by 92.92%
$24 Appendix 4C - quarterly 31 Jul 2007 8:52AM $0.260 $0.017 fallen by 93.46%
$24 Open Briefing 18 Jul 2007 10:07AM $0.310 $0.017 fallen by 94.52%
$24 BioDiems eye peptide BDM E repairs retinal damage in mice 2 Jul 2007 10:37AM $0.275 $0.017 fallen by 93.82%
$24 Russians trial a new way of making pandemic flu vaccine 24 May 2007 10:25AM $0.350 $0.017 fallen by 95.14%
$24 BioDiem completes recruitment of patients for clinical trial 30 Apr 2007 10:21AM $0.325 $0.017 fallen by 94.77%
$24 Commitments Test Entity - Third Quarter Report 26 Apr 2007 3:16PM $0.330 $0.017 fallen by 94.85%
$24 New Patent Filed for BDM-E 9 Mar 2007 9:42AM $0.320 $0.017 fallen by 94.69%

401 - 425 of 458 results

Page 17 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.